CA2442428A1 - Nouveaux inhibiteurs de la tyrosine kinase - Google Patents
Nouveaux inhibiteurs de la tyrosine kinase Download PDFInfo
- Publication number
- CA2442428A1 CA2442428A1 CA002442428A CA2442428A CA2442428A1 CA 2442428 A1 CA2442428 A1 CA 2442428A1 CA 002442428 A CA002442428 A CA 002442428A CA 2442428 A CA2442428 A CA 2442428A CA 2442428 A1 CA2442428 A1 CA 2442428A1
- Authority
- CA
- Canada
- Prior art keywords
- methyl
- pyridin
- hydroxy
- ethylamino
- phenyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
L'invention concerne des composés correspondant à la formule (I) et des sels pharmaceutiquement acceptables de ces composés. Lesdits composés inhibent les enzymes du type tyrosine kinase et peuvent donc être utilisés comme agent anticancéreux. Ces composés sont également utiles pour le traitement d'autres maladies qui peuvent être traitées par inhibition des enzymes du type tyrosine kinase.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US27932701P | 2001-03-28 | 2001-03-28 | |
US60/279,327 | 2001-03-28 | ||
PCT/US2002/009402 WO2002079192A1 (fr) | 2001-03-28 | 2002-03-26 | Nouveaux inhibiteurs de la tyrosine kinase |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2442428A1 true CA2442428A1 (fr) | 2002-10-10 |
Family
ID=23068491
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002442428A Abandoned CA2442428A1 (fr) | 2001-03-28 | 2002-03-26 | Nouveaux inhibiteurs de la tyrosine kinase |
Country Status (25)
Country | Link |
---|---|
EP (1) | EP1381598A4 (fr) |
JP (1) | JP2004534010A (fr) |
KR (1) | KR20030083016A (fr) |
CN (1) | CN1514833A (fr) |
AR (1) | AR035804A1 (fr) |
BG (1) | BG108206A (fr) |
BR (1) | BR0208373A (fr) |
CA (1) | CA2442428A1 (fr) |
CZ (1) | CZ20032615A3 (fr) |
EE (1) | EE200300475A (fr) |
GE (1) | GEP20053660B (fr) |
HR (1) | HRP20030844A2 (fr) |
HU (1) | HUP0400323A2 (fr) |
IL (1) | IL158041A0 (fr) |
IS (1) | IS6968A (fr) |
MX (1) | MXPA03008690A (fr) |
NO (1) | NO20034308L (fr) |
PE (1) | PE20021015A1 (fr) |
PL (1) | PL373300A1 (fr) |
RU (1) | RU2003131693A (fr) |
SK (1) | SK12002003A3 (fr) |
UY (1) | UY27234A1 (fr) |
WO (1) | WO2002079192A1 (fr) |
YU (1) | YU84603A (fr) |
ZA (1) | ZA200307466B (fr) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7081454B2 (en) * | 2001-03-28 | 2006-07-25 | Bristol-Myers Squibb Co. | Tyrosine kinase inhibitors |
MXPA04008408A (es) | 2002-03-01 | 2004-11-29 | Squibb Bristol Myers Co | Mamiferos no humanos, transgenicos, que expresan receptores de la tirosina cinasa activados constitutivamente. |
MXPA04012440A (es) * | 2002-06-12 | 2005-04-28 | Abbott Lab | Antagonistas de receptor de hormona concentradora de melanina. |
AU2003293333A1 (en) * | 2002-12-02 | 2004-06-23 | Arqule, Inc. | Method of treating cancers |
US7189716B2 (en) | 2003-01-03 | 2007-03-13 | Bristol-Myers Squibb Company | Tyrosine kinase inhibitors |
JP2006516626A (ja) * | 2003-01-28 | 2006-07-06 | スミスクライン ビーチャム コーポレーション | 化学的化合物 |
US7312215B2 (en) | 2003-07-29 | 2007-12-25 | Bristol-Myers Squibb Company | Benzimidazole C-2 heterocycles as kinase inhibitors |
EP1663204B1 (fr) | 2003-08-29 | 2014-05-07 | Exelixis, Inc. | Modulateurs c-kit et leurs procedes d'utilisation |
US20050075358A1 (en) * | 2003-10-06 | 2005-04-07 | Carboni Joan M. | Methods for treating IGF1R-inhibitor induced hyperglycemia |
DE102004010207A1 (de) * | 2004-03-02 | 2005-09-15 | Aventis Pharma S.A. | Neue 4-Benzimidazol-2-yl-pyridazin-3-on-Derivate |
TW201134828A (en) | 2004-04-02 | 2011-10-16 | Osi Pharm Inc | 6,6-bicyclic ring substituted heterobicyclic protein kinase inhibitors |
CA2591413A1 (fr) * | 2004-12-16 | 2006-06-22 | Vertex Pharmaceuticals Incorporated | Pyrid-2-ones utiles comme inhibiteurs de proteine kinases de la famille tec pour le traitement de maladies inflammatoires, proliferatives et a mediation immunologique |
WO2006130657A2 (fr) | 2005-05-31 | 2006-12-07 | Bristol-Myers Squibb Company | Procede de reduction stereoselective pour la preparation de composes de pyrrolotriazine |
CA2618360C (fr) | 2005-08-04 | 2015-06-09 | Sirtris Pharmaceuticals, Inc. | Benzothiazols et thiazolopyridines en tant que modulateurs de sirtuine |
US8093401B2 (en) | 2005-08-04 | 2012-01-10 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
US8088928B2 (en) | 2005-08-04 | 2012-01-03 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
US7855289B2 (en) | 2005-08-04 | 2010-12-21 | Sirtris Pharmaceuticals, Inc. | Sirtuin modulating compounds |
EP1919905B1 (fr) | 2005-08-29 | 2011-02-23 | Vertex Pharmaceuticals Incorporated | Pyrid-2-ones disubstituées en 3, 5, inhibitrices de la famille tec des tyrosine kinases non liées aux recepteurs |
ATE548363T1 (de) | 2005-08-29 | 2012-03-15 | Vertex Pharma | 3,5-disubstituierte pyrid-2-one, die sich als inhibitoren der tec-familie von nicht-rezeptor- tyrosinkinasen eignen |
EP1919906B1 (fr) | 2005-08-29 | 2011-10-12 | Vertex Pharmaceuticals Incorporated | Pyrid-2-ones disubstituees en 3, 5 inhibitrices de la famille tec des tyrosine kinases non receptrices |
WO2007026720A1 (fr) * | 2005-08-31 | 2007-03-08 | Taisho Pharmaceutical Co., Ltd. | Derive de pyrazole a noyau condense |
US8575164B2 (en) | 2005-12-19 | 2013-11-05 | OSI Pharmaceuticals, LLC | Combination cancer therapy |
WO2007145203A1 (fr) * | 2006-06-13 | 2007-12-21 | Daiichi Fine Chemical Co., Ltd. | 2-amino-1-(4-fluorophenyl) éthanol optiquement actif |
US8063225B2 (en) | 2006-08-14 | 2011-11-22 | Chembridge Corporation | Tricyclic compound derivatives useful in the treatment of neoplastic diseases, inflammatory disorders and immunomodulatory disorders |
WO2008022747A1 (fr) * | 2006-08-21 | 2008-02-28 | F. Hoffmann-La Roche Ag | Dérivés tricycliques de lactame, leur fabrication et leur emploi en tant qu'agents pharmaceutiques |
WO2008025526A1 (fr) * | 2006-08-31 | 2008-03-06 | F. Hoffmann-La Roche Ag | Dérivés d'indole, fabrication de ceux-ci et utilisation comme agents pharmaceutiques |
EP2145021A2 (fr) | 2007-05-17 | 2010-01-20 | Bristol-Myers Squibb Company | Biomarqueurs et procédés pour déterminer la sensibilité de modulateurs de récepteur de facteur de croissance de type 1 semblable à l'insuline |
TW200916472A (en) | 2007-06-20 | 2009-04-16 | Sirtris Pharmaceuticals Inc | Sirtuin modulating compounds |
CA2690064A1 (fr) * | 2007-06-25 | 2008-12-31 | Guy Georges | Derives amido du benzimidazole en tant qu'inhibiteurs de kinase |
EP2065380A1 (fr) * | 2007-08-22 | 2009-06-03 | F.Hoffmann-La Roche Ag | Dérivés de pyridoneamide comme inhibiteurs de focal adhesion kinase (FAK) et leur utilisation pour le traitement du cancer |
US7816540B2 (en) * | 2007-12-21 | 2010-10-19 | Hoffmann-La Roche Inc. | Carboxyl- or hydroxyl-substituted benzimidazole derivatives |
MX2010007525A (es) | 2008-01-22 | 2010-08-18 | Vernalis R&D Ltd | Derivados de indolil-piridona que tienen actividad inhibitoria de la cinasa 1 de punto de control. |
JP2011520970A (ja) | 2008-05-19 | 2011-07-21 | オーエスアイ・フアーマスーテイカルズ・インコーポレーテツド | 置換されたイミダゾピラジン類およびイミダゾトリアジン類 |
MY160006A (en) | 2008-12-19 | 2017-02-15 | Sirtris Pharmaceuticals Inc | Thiazolopyridine sirtuin modulating compounds |
DE102010001064A1 (de) * | 2009-03-18 | 2010-09-23 | Bayer Schering Pharma Aktiengesellschaft | Substituierte 2-Acetamido-5-Aryl-1,2,4-triazolone und deren Verwendung |
JP2012524119A (ja) | 2009-04-20 | 2012-10-11 | オーエスアイ・ファーマシューティカルズ,エルエルシー | C−ピラジン−メチルアミンの調製 |
US8536180B2 (en) * | 2009-05-27 | 2013-09-17 | Abbvie Inc. | Pyrimidine inhibitors of kinase activity |
EP2494070A2 (fr) | 2009-10-30 | 2012-09-05 | Bristol-Myers Squibb Company | Méthodes pour traiter un cancer chez des patients présentant une résistance à l'inhibiteur d'igf-1r |
EA022623B1 (ru) * | 2010-10-06 | 2016-02-29 | ГЛАКСОСМИТКЛАЙН ЭлЭлСи | Производные бензимидазола в качестве ингибиторов pi3-киназ |
WO2012061169A1 (fr) * | 2010-11-01 | 2012-05-10 | Boehringer Ingelheim International Gmbh | Inhibiteurs benzimidazole de production de leucotriènes |
EP2766497A1 (fr) | 2011-10-13 | 2014-08-20 | Bristol-Myers Squibb Company | Procédés de sélection et de traitement du cancer chez des patients au moyen d'inhibiteurs de l'igf-1r/ir |
EP3010918B1 (fr) | 2013-06-21 | 2018-08-15 | Zenith Epigenetics Ltd. | Nouveaux composés bicycliques substitués utilisés comme inhibiteurs de bromodomaines |
PL3010503T3 (pl) | 2013-06-21 | 2020-08-24 | Zenith Epigenetics Ltd. | Nowe bicykliczne inhibitory bromodomen |
EP3027604B1 (fr) | 2013-07-31 | 2019-02-20 | Zenith Epigenetics Ltd. | Nouvelles quinazolones en tant qu'inhibiteurs de bromodomaine |
CN103936719A (zh) * | 2014-05-14 | 2014-07-23 | 中国药科大学 | 苯并咪唑类衍生物制备方法及用途 |
JP2017525351A (ja) | 2014-07-30 | 2017-09-07 | イェダ リサーチ アンド ディベロップメント カンパニー リミテッドYeda Research And Development Co.Ltd. | 多能性幹細胞の培養用培地 |
EP3227281A4 (fr) | 2014-12-01 | 2018-05-30 | Zenith Epigenetics Ltd. | Pyridinones substituées utilisées comme inhibiteurs de bromodomaines |
WO2016092375A1 (fr) | 2014-12-11 | 2016-06-16 | Zenith Epigenetics Corp. | Hétérocycles substitués à titre d'inhibiteurs de bromodomaines |
CA2966450A1 (fr) | 2014-12-17 | 2016-06-23 | Olesya KHARENKO | Inhibiteurs de bromodomaines |
CA2982664A1 (fr) * | 2015-04-16 | 2016-10-20 | Merck Patent Gmbh | Derives de 3-(1h-benzimidazol-2-yl)-1h-pyridin-2-one |
EP3914698A1 (fr) | 2019-01-23 | 2021-12-01 | Yeda Research and Development Co. Ltd | Milieux de culture pour cellules souches pluripotentes |
CN117069696B (zh) * | 2023-08-17 | 2024-04-26 | 中国药科大学 | 一种双靶点小分子抑制剂及其制备方法和应用 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6162804A (en) * | 1997-09-26 | 2000-12-19 | Merck & Co., Inc. | Tyrosine kinase inhibitors |
PL206826B1 (pl) * | 1999-06-23 | 2010-09-30 | Sanofi Aventis Deutschland | Podstawione benzimidazole |
US7081454B2 (en) * | 2001-03-28 | 2006-07-25 | Bristol-Myers Squibb Co. | Tyrosine kinase inhibitors |
-
2002
- 2002-03-26 YU YU84603A patent/YU84603A/sh unknown
- 2002-03-26 MX MXPA03008690A patent/MXPA03008690A/es unknown
- 2002-03-26 BR BR0208373-6A patent/BR0208373A/pt not_active IP Right Cessation
- 2002-03-26 CZ CZ20032615A patent/CZ20032615A3/cs unknown
- 2002-03-26 RU RU2003131693/04A patent/RU2003131693A/ru not_active Application Discontinuation
- 2002-03-26 EP EP02723631A patent/EP1381598A4/fr not_active Withdrawn
- 2002-03-26 PL PL02373300A patent/PL373300A1/xx not_active Application Discontinuation
- 2002-03-26 IL IL15804102A patent/IL158041A0/xx unknown
- 2002-03-26 KR KR10-2003-7012594A patent/KR20030083016A/ko not_active Application Discontinuation
- 2002-03-26 WO PCT/US2002/009402 patent/WO2002079192A1/fr active Application Filing
- 2002-03-26 GE GE5363A patent/GEP20053660B/en unknown
- 2002-03-26 SK SK12002003A patent/SK12002003A3/sk not_active Application Discontinuation
- 2002-03-26 JP JP2002577817A patent/JP2004534010A/ja not_active Withdrawn
- 2002-03-26 EE EEP200300475A patent/EE200300475A/xx unknown
- 2002-03-26 HU HU0400323A patent/HUP0400323A2/hu unknown
- 2002-03-26 CA CA002442428A patent/CA2442428A1/fr not_active Abandoned
- 2002-03-26 CN CNA028105168A patent/CN1514833A/zh active Pending
- 2002-03-27 UY UY27234A patent/UY27234A1/es not_active Application Discontinuation
- 2002-03-27 AR ARP020101167A patent/AR035804A1/es not_active Application Discontinuation
- 2002-03-27 PE PE2002000244A patent/PE20021015A1/es not_active Application Discontinuation
-
2003
- 2003-09-25 ZA ZA200307466A patent/ZA200307466B/en unknown
- 2003-09-26 BG BG108206A patent/BG108206A/bg unknown
- 2003-09-26 NO NO20034308A patent/NO20034308L/no not_active Application Discontinuation
- 2003-09-26 IS IS6968A patent/IS6968A/is unknown
- 2003-10-17 HR HR20030844A patent/HRP20030844A2/hr not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AR035804A1 (es) | 2004-07-14 |
PE20021015A1 (es) | 2002-11-10 |
EP1381598A1 (fr) | 2004-01-21 |
SK12002003A3 (en) | 2004-10-05 |
IS6968A (is) | 2003-09-26 |
EE200300475A (et) | 2004-02-16 |
KR20030083016A (ko) | 2003-10-23 |
HRP20030844A2 (en) | 2005-08-31 |
NO20034308D0 (no) | 2003-09-26 |
EP1381598A4 (fr) | 2008-03-19 |
GEP20053660B (en) | 2005-11-10 |
NO20034308L (no) | 2003-11-26 |
JP2004534010A (ja) | 2004-11-11 |
HUP0400323A2 (hu) | 2005-11-28 |
BG108206A (bg) | 2004-11-30 |
IL158041A0 (en) | 2004-03-28 |
RU2003131693A (ru) | 2005-05-10 |
WO2002079192A1 (fr) | 2002-10-10 |
MXPA03008690A (es) | 2003-12-12 |
CN1514833A (zh) | 2004-07-21 |
CZ20032615A3 (en) | 2004-03-17 |
ZA200307466B (en) | 2005-01-13 |
YU84603A (sh) | 2006-03-03 |
UY27234A1 (es) | 2002-10-31 |
PL373300A1 (en) | 2005-08-22 |
BR0208373A (pt) | 2005-02-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2442428A1 (fr) | Nouveaux inhibiteurs de la tyrosine kinase | |
US7081454B2 (en) | Tyrosine kinase inhibitors | |
CA2534921C (fr) | Composes d'aminotriazole utiles en tant qu'inhibiteurs des proteines kinases | |
US7232826B2 (en) | Tyrosine kinase inhibitors | |
US7470696B2 (en) | Tyrosine kinase inhibitors | |
US8129403B2 (en) | Chemical compounds | |
US6515004B1 (en) | N-[5-[[[5-alkyl-2-oxazolyl]methyl]thio]-2-thiazolyl]-carboxamide inhibitors of cyclin dependent kinases | |
JP5261575B2 (ja) | 化学化合物 | |
KR20130028732A (ko) | 4―아미노피리미딘 유도체 및 아데노신 a2a 수용체 안타고니스트로서의 이들의 용도 | |
US20080113967A1 (en) | Enzyme modulators and treatments | |
US9346795B2 (en) | Substituted sulfonamides useful as antiapoptotic Bcl inhibitors | |
AU2004212421A1 (en) | Heteroaryl substituted pyrolls useful as inhibitors of protein kinases | |
EA007968B1 (ru) | N-замещённые производные пирролидина в качестве ингибиторов дипептидилпептидазы | |
MXPA04008807A (es) | Derivados de 4-(imidazol-5-il)-2-(4-sulfonilanilino)pirimidina con actividad inhibidora de cdk. | |
US20100029643A1 (en) | Heterocyclyc sulfonamides having edg-1 antagonistic activity | |
CA2547080A1 (fr) | Inhibiteurs heterocycliques de proteine kinase et leurs utilisations | |
CA3079081A1 (fr) | Derives de benzimidazole et leurs utilisations | |
CA2389280C (fr) | Triazoles utilises comme inhibiteurs de farnesyl transferase | |
TW202220980A (zh) | 新穎二唑系選擇性hdac6抑制劑 | |
JP2003522174A (ja) | サイクリン依存性キナーゼの3−アミノピラゾール阻害剤 | |
AU2003251721A1 (en) | Azole methylidene cyanide derivatives and their use as protein kinase modulators | |
AU2002254399A1 (en) | Novel tyrosine kinase inhibitors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued |